Abstract
Triple-negative breast cancer (TNBC) is associated with poor prognosis owing to its aggressive and heterogeneous nature, and the lack of therapeutic targets. Although Forkhead Box M1 (FOXM1) is one of the most important oncogenes contributing to tumorigenesis, progression, and drug resistance in TNBC, the underlying molecular mechanisms are not well understood. Emerging evidence indicates that autophagy plays a critical role in cell survival and protective mechanism in TNBC. However, signaling pathways that are involved in the regulation of autophagy remain to be elucidated. In the present study, we examined the role of FOXM1 in regulating autophagy in TNBC cells and found that FOXM1 is upregulated during induction of autophagy. We found that inhibition of FOXM1 suppressed starvation and rapamycin-induced autophagy and expression of the major autophagy regulators, LC3 and Beclin-1. Further studies demonstrated that FOXM1 directly binds to the promotors of LC3 and Beclin-1 genes and transcriptionally regulates their expression by chromatin immunoprecipitation (ChIP) and luciferase gene reporter assays. In conclusion, our study provides the first evidence about the role of FOXM1 in regulating expression of LC3 and Beclin-1 and autophagy in TNBC cells. Our findings provide novel insight into the role of FOXM1 regulation of the autophagic survival pathway and potential molecular target for treating TNBC.
Key messages
• FOXM1 promotes tumorigenesis and progression of TNBC. However, the underlying molecular mechanism by which FOXM1 promotes TNBC tumorigenesis is unclear. The goal of our study was to determine the role of FOXM1 in the regulation of autophagy that plays a role in TNBC progression. Our findings show that FOXM1 binds to promoters of the genes encoding the major autophagy proteins, Beclin and LC3, and provide new insights into the regulation of autophagy, which is being targeted in many clinical trials.
Similar content being viewed by others
Abbreviations
- TNBC:
-
Triple-negative breast cancer
- FOXM1:
-
Forkhead Box M1
- LC3:
-
Microtubule-associated light chain 3
- ChIP:
-
Chromatin immunoprecipitation
- ER:
-
Estrogen receptors
- HR:
-
Hormone receptors
- HER2:
-
Human epidermal growth factor receptor 2
- PR:
-
Progesterone receptor
- eEF2K:
-
Eukaryotic elongation factor 2 kinase
- RT-PCR:
-
Reverse transcriptase and polymerase chain reaction
- AVOs:
-
Acidic vesicular organelles
- Atg:
-
Autophagy-related genes
- siRNAs:
-
Small interfering RNAs
- BS:
-
Binding sites
- PBS:
-
Phosphate-buffered saline
- TBST:
-
Tris-buffered saline–Tween 20
- cDNA:
-
Complementary DNA
References
PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002–2018. Breast Cancer Treatment (PDQ®): Patient Version, PDQ Adult Treatment Editorial Board 2018
Narrandes S, Huang S, Murphy L, Xu W (2018) The exploration of contrasting pathways in triple negative breast cancer (TNBC). BMC Cancer 18:22
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, on behalf of; EVA Study Group (2017) Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: new insights beyond clinical trials. The EVA study. Breast 35:115–121
Guo W, Lin L, He X, He F, Wang C, Chen N, Wang Y (2017) Biomarkers of DNA repair and related pathways: significance of treatment in triple-negative breast cancer. Crit Rev Oncog 22:427–437
Engebraaten O, Vollan HKM, Børresen-Dale AL (2013) Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 183:1064–1074
Abba MC, Lacunza E, Butti M, Aldaz CM (2010) Breast cancer biomarker discovery in the functional genomic age: a systematic review of 42 gene expression signatures. Biomark Insights 27:103–118
The Cancer Genome Atlas Network (2013) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
Lu XF, Zeng, Liang WQ, Chen CF, Sun SM, Lin HY (2018) FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget 9:842–852
Song X, Fiati Kenston SS, Zhao J, Yang D, Gu Y (2017) Roles of FoxM1 in cell regulation and breast cancer targeting therapy. Med Oncol 34:41
Yang X, Shi Y, Yan J, Fan H (2018) Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells. Am J Transl Res 10:629–638
Yang H, Wen L, Wen M, Liu T, Zhao L, Wu B, Yun Y, Liu W, Wang H, Wang Y, Wen N (2018) FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-met/AKT-dependent positive feedback loop. Anti-Cancer Drugs 29:216–226
Fei BY, He X, Ma J, Zhang M, Chai R (2017) FoxM1 is associated with metastasis in colorectal cancer through induction of the epithelial-mesenchymal transition. Oncol Lett 14:6553–6561
Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, Ali R, Sarkar FH (2016) Retraction note to: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 158:607
Hamurcu Z, Ashour A, Kahraman N, Ozpolat B (2016) FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget 7:16619–16635
Ozpolat B, Benbrook DM (2015) Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res 7:291–299
Zhou Y, Rucker EB 3rd, Zhou BP (2016) Autophagy regulation in the development and treatment of breast cancer. Acta Biochim Biophys Sin Shanghai 48:60–74
Mizushima N (2017) The exponential growth of autophagy-related research: from the humble yeast to the Nobel prize. FEBS Lett 591:681–689
Tang DY, Ellis RA, Lovat PE (2016) Prognostic impact of autophagy biomarkers for cutaneous melanoma. Front Oncol 6:236 eCollection
Hamurcu Z, Delibaşı N, Geçene S, Şener EF, Dönmez-Altuntaş H, Özkul Y, Canatan H, Ozpolat B (2018) Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of cyclin-D1 and uPAR/integrin β1/ Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol 144:415–430
Wang X, Xie J, Christopher G (2017) Proud. Eukaryotic elongation factor 2 kinase (eEF2K) in cancer. Cancers (Basel) 9:162
Hamurcu Z, Kahraman N, Ashour A, Ozpolat B (2017) FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer. Breast Cancer Res Treat 163:485–493
Deng Q, Wang Z, Wang L, Zhang L, Xiang X, Wang Z, Chong T (2013) Lower mRNA and protein expression levels of LC3 and Beclin1, markers of autophagy, were correlated with progression of renal clear cell carcinoma. Jpn J Clin Oncol 43:1261–1268
Kusuzaki K, Matsubara T, Satonaka H, Matsumine A, Nakamura T, Sudo A, Murata H, Hosogi S, Baldini N (2014) Intraoperative photodynamic surgery (iPDS) with Acridine Orange for musculoskeletal sarcomas. Cureus 6:e204
Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B (2013) Therapeutic silencing of Bcl-2 by systemically administered siRNA Nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (−) and ER (+) breast Cancer. Mol Ther Nucleic Acids 2:e121
Dreos R, Ambrosini G, Périer RC, Bucher P (2014) The eukaryotic promoter database: expansion of EPDnew and new promoter analysis tools. Nucleic Acids Res 43(Database issue):D92–D96
Zhu H, Yang X, Liu J, Zhou L, Zhang C, Xu L, Qin Q, Zhan L, Lu J, Cheng H, Sun X (2015) Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells. Cell Stress Chaperones 20:217–220
Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN (1999) Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 79:59–64
Paquette M, El-Houjeiri L, Pause A (2018) mTOR pathways in cancer and autophagy. Cancers (Basel) 10(1):E18
Civiletto G, Dogan SA, Cerutti R, Fagiolari G, Moggio M, Lamperti C, Benincá C, Viscomi C, Zeviani M (2018) Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis. EMBO Mol Med 10(11):e8799
Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH, Ahn SD, Cho EY, Gong G (2016) Expression of FOXM1 and related proteins in breast cancer molecular subtypes. Int J Exp Pathol 97:170–177
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1–222
Ye X, Zhang Y, He B, Meng Y, Li Y, Gao Y (2015) Quantitative proteomic analysis identifies new effectors of FOXM1 involved in breast cancer cell migration. Int J Clin Exp Pathol 8:15836–15844
Barsotti AM, Prives C (2009) Pro-proliferative FoxM1 is a target of p53- mediated repression. Oncogene 28:4295–4305
Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY et al (2001) Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 507:59–66
Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH (2005) Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25:10875–10894
Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M (2013) Cancer genetics and genomics of human FOX family genes. Cancer Lett 328:198–206
Wierstra I (2013) The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 118:97–398
Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q (2013) High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol 30:475
Choi J, Jung W, Koo JS (2013) Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 62:275–286
Zhong S, Zhou A, Qi F, Li Z, Yu Z, Lu Y, Liu X (2017) Downregulating forkhead box M1 inhibits proliferation by inhibiting autophagy in the sw480 cell line. Biomed Rep 7:47–50
Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu Y, Ouyang L (2018) Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif 51:e12402
Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B (2012) Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 7:e41171
Lefort S, Joffre C, Kieffer Y, Givel AM, Bourachot B, Zago G, Bieche I, Dubois T, Meseure D, Vincent-Salomon A, Camonis J, Mechta-Grigoriou F (2014) Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy 10:2122–2142
Nandi D, Cheema PS, Jaiswal N, Nag A (2017) FoxM1: repurposing an oncogene as a biomarker. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer
Gartel A (2015) Targeting FOXM1 auto-regulation in cancer. Cancer Biol Ther 16:185–186
Gartel AL (2017) FOXM1 in cancer: interactions and vulnerabilities. Cancer Res 77:3135–3139
Dikic I, Elazar Z (2018) Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol 19:349–364
Mrakovcic M, Fröhlich LF (2018) p53-mediated molecular control of autophagy in tumor cells. Biomolecules 8:E14
Lee YK, Lee JA (2016) Role of the mammalian ATG8/LC3 family in autophagy: differential and compensatory roles in the spatiotemporal regulation of autophagy. BMB Rep 49:424–430
Saba R, Alsayed A, Zacny JP, Dudek AZ (2016) The role of Forkhead box protein M1 in breast cancer progression and resistance to therapy. Int J Breast Cancer 2016:1–8
Miyashita A, Fukushima S, Nakahara S, Yamashita J, Tokuzumi A, Aoi J, Ichihara A, Kanemaru H, Jinnin M, Ihn H (2015) Investigation of FOXM1 as a potential new target for melanoma. PLoS One 10:e0144241
Zhang J, Wang G, Zhou Y, Chen Y, Ouyang L, Liu B (2018) Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy. Cell Mol Life Sci 75:1803–1826
Funding
This study was funded by The Scientific and Technological Research Council –TÜBİTAK- research grant (grant number 214S204) and Research Fund of the Erciyes University (Project number: TDA-2016-6415).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hamurcu, Z., Delibaşı, N., Nalbantoglu, U. et al. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells. J Mol Med 97, 491–508 (2019). https://doi.org/10.1007/s00109-019-01750-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-019-01750-8